Inventiva Finalizes EIB Warrant Restructuring, Eliminates Anti-Dilution Overhang
IVA sits 59% above its 52-week low of $2.854 on elevated volume (2.1× avg).
Summary
Inventiva completed the final step of its June 2 refinancing by issuing 15.7 million new EIB warrants and canceling the remaining legacy warrants. The new warrants have a nominal exercise price of €0.01 and no anti-dilution protection, removing a key source of uncertainty. If fully exercised, they would represent about 6.5% of current share capital. This follows the June 12 repayment of EIB loans and repurchase of most legacy warrants, marking the end of a multi-step capital structure overhaul. The simplified warrant terms reduce potential future dilution and improve alignment with shareholders.
At the time of this announcement, IVA was trading at $4.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $2.85 to $7.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.